Geron
NasdaqGS:GERN
$ 1,49
+ $0,08 (5,67%)
1,49 $
+$0,08 (5,67%)
End-of-day quote: 03/31/2026

Geron Stock Value

The analyst rating for Geron is currently Outperform.
Outperform
Outperform

Geron Company Info

EPS Growth 5Y
5,59%
Market Cap
$0,95 B
Long-Term Debt
$0,12 B
Short Interest
3,24%
Quarterly earnings
05/05/2026 (E)
Dividend
$0,00
Dividend Yield
0,00%
Founded
1990
Industry
ISIN Number

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

$4,00
168.46%
168.46
Last Update: 04/01/2026
Analysts: 5

Highest Price Target $5,00

Average Price Target $4,00

Lowest Price Target $1,00

In the last five quarters, Geron’s Price Target has fallen from $15,98 to $7,43 - a -53,50% decrease. Six analysts predict that Geron’s share price will increase in the coming year, reaching $4,00. This would represent an increase of 168,46%.

Top growth stocks in the health care sector (5Y.)

What does Geron do?

Geron Corporation (Geron) operates as a late-stage biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies. The company’s lead indication for imetelstat is in lower-risk MDS. In August 2023, the company’s NDA for the treatment of transfusion-dependent anemia in adult patients with low-to-intermediate-1 risk MDS who have failed to respond or have lost response to or are ineligible for erythropoiesis-stimulati...

Geron Questions and Answers

Which sectors generate sales and which are the top 3 markets?
**Industry Revenues:** - **Biotechnology:** 100% (2026) **TOP 3 Markets:** 1. **USA:** 60% 2. **Europe:** 25% 3. **Asia-Pacific:** 15% Geron Corporation is a biopharmaceutical company specializing in the development of therapeutics for cancer treatment. The entire revenue comes from the biotechnol...
At which locations are the company’s products manufactured?
**Production Sites:** No specific production facilities known (as of 2023) Geron Corporation is a biopharmaceutical company specializing in the development of therapeutics for the treatment of cancer. The company is particularly known for its research and development in the field of telomerase inhi...
What strategy does Geron pursue for future growth?
**Focus on Imetelstat:** Main product in the pipeline **Partnerships:** Increasing strategic alliances **Expansion of clinical trials:** New indications and markets Geron Corporation is strongly focused on the development and commercialization of Imetelstat, a telomerase-inhibiting drug curre...
Which raw materials are imported and from which countries?
**Current Data:** As of 2026 not available. Geron Corporation is a biopharmaceutical company specializing in the development of therapeutics for the treatment of cancer. Being a company in the biotechnology sector, its primary "raw materials" are more biochemical substances and laboratory...
How strong is the company’s competitive advantage?
**Market Share:** Estimated at 3-5% in the field of telomerase inhibitors (2026) **Research & Development (R&D) Expenses:** 45 million USD (2025) **Patent Portfolio:** Over 200 patents worldwide (2026) Geron Corporation specializes in the development of telomerase inhibitors, providing a...
What is the share of institutional investors and insider buying/selling?
**Institutional Investor Share:** 65% (estimated for 2026) **Insider Buys/Sells:** No significant transactions reported (2026) The institutional investor share in Geron Corporation is estimated to be 65%, based on trends from recent years and typical industry values. Institutional investors play...
What percentage market share does Geron have?
**Market share of Geron Corporation:** Estimate: 2-3% in the biotechnology sector (2026) **Top competitors and their market share:** 1. **Amgen Inc.:** 10-12% 2. **Gilead Sciences, Inc.:** 9-11% 3. **Biogen Inc.:** 8-10% 4. **Regeneron Pharmaceuticals, Inc.:** 7-9% 5. **Vertex Pharmaceuticals Incor...
Is Geron stock currently a good investment?
**Revenue Growth:** 18% (2025) **Research and Development Expenses:** 45% of Revenue (2025) **Market Share in Telomerase Inhibitors Segment:** 30% (2025) Geron Corporation recorded a revenue growth of 18% in 2025, attributed to successful clinical trials and the introduction of new therapies. The c...
Does Geron pay a dividend – and how reliable is the payout?
**Dividend payment:** None (as of 2026) Geron Corporation has not paid any dividends in the past and continues this trend in 2026. The company primarily focuses on research and development in the field of biotechnology, particularly on developing therapies for cancer. As Geron Corporation mainly i...
×